Full-Time

Analyst - Deliver Excellence

Supply Chain

Posted on 10/3/2025

Deadline 10/8/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$61k - $97.8k/yr

+ Annual Performance Bonus

San Jose, CA, USA

In Person

Category
Operations & Logistics (1)
Required Skills
Visio
Word/Pages/Docs
Tableau
Customer Service
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • BA Degree or 2+ years of experience in transportation, logistics or customer service; or equivalent combination of education and experience. However, Bachelor’s degree is preferred
  • Strong financial acumen – the ability to utilize fundamental concepts of finance to manage budgets, forecast costs, and provide relevant information for decision-making.
  • Experience with Six Sigma or other process improvement methodology
  • Knowledge in Microsoft Office Suite (Excel, Word and PowerPoint). However, possessing advanced knowledge and experience with any of these is desired: Tableau, Visio, Pivot Tables.
  • Creative thinking ability: It is essential that they can demonstrate originality and imagination in thinking while developing a solution to a problem
  • Communication skills: Communicate clearly both orally and in writing, and present technical information clearly and succinctly across a variety of communication settings and audience
  • Customer focused – applicant must think and act from customer perspective
  • Detail-orientation: Ability to provide holistic solutions and approach problems systematically and develop scalable solutions
  • Flexibility: Ability to function in a highly dynamic, fast paced environment
  • Highly organized and able to multi-task with a clear bias for action and a sense of urgency on priorities
  • Able to handle high pressure and adverse situations with composure. Possess resilience and perseverance in the face of constraints
  • Team player: They must be able to work well with others in a fast paced and dynamic environment
  • Excellent problem-solving and analytical skills: Able to clarify and resolve complex business issues by breaking them down into meaningful components to determine root cause, and to redesign internal and external business processes where necessary.
Responsibilities
  • Collect data on every step of the supply chain, from receipt to delivery, create dashboards and maintain databases to safely store information.
  • Analyze all steps of the supply chain. This includes reviewing statistical data and transportation routes to identify ways to streamline logistics and maximize company profits.
  • Monitor shipments and trace shipment routes, as required, to ensure that the most efficient shipping and delivery methods are used for shipment delivery.
  • Responsible for developing and maintaining cost estimates, forecasts, and cost models.
  • Execute day to day processes and perform data management applying a combination of data mining, data modeling, and data analysis; cost/benefit analysis and/or problem analysis.
  • Undertake ad-hoc queries and maintain reports from a variety of resources as specific to department or organizational needs to support the business.
  • Responsible for conducting analysis and creating reports and presentations of weekly and monthly KPIs and forecasts.
  • Actively participate in transportation alignment and tracking performance /costs.
  • Correct freight settlement documents to ensure the proper accruing of freight.
  • Estimate distribution costs for new business opportunities-indirect/direct freight.
  • Responsible for performing cost comparisons against various scenarios and options.
  • Clearly communicate to senior leaders (both internal and external), suppliers and customers.
Desired Qualifications
  • Experience with Six Sigma or other process improvement methodology
  • Possessing advanced knowledge and experience with any of these is desired: Tableau, Visio, Pivot Tables.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE